Navigation Links
CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
Date:4/27/2009

ation agents, the L.E.A.P.S. activated dendritic cells did not produce the inflammatory cytokines that are usually associated with IL-12 production. Untreated monocytes or monocytes treated with the HSV or HIV portion of the vaccine conjugate alone were unchanged and did not express any of the dendritic cell characteristics.

Dendritic cells direct the subsequent immune response to a vaccine by presenting the vaccine's antigen(s) to the appropriate T lymphocyte and then deliver specific cytokine proteins to the T cell to determine the immune response outcome to the specific vaccine. "L.E.A.P.S. vaccines are unique in their ability to interact with, activate and cause differentiation and maturation of dendritic cell towards a protective immune response without the production of pro-inflammatory cytokines," said Dr. Rosenthal.

The two lead product candidates being developed are CEL-1000 and CEL-2000 from the L.E.A.P.S. technology. CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines. CEL-2000, a L.E.A.P.S. vaccine incorporating a peptide from a rheumatoid arthritis disease protein, was shown to curtail the progression of tissue damage caused by rheumatoid arthritis.

"It is very exciting to see the effect of L.E.A.P.S. vaccines on isolated human immature dendritic cells using a simple molecule, in two different instances," said Dr. Dan Zimmerman, the inventor of the L.E.A.P.S. technology. "I am hopeful that other L.E.A.P.S. vaccine candidates, such as CEL-2000 being developed as a vaccine for rheumatoid arthritis, can also be used with comparable results in humans. The lack of proinflammatory cytokine production in responses to the L.E.A.P.S.
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCI to Present at the Noble Financial Conference
2. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
3. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Takes Delivery of New Manufacturing Facility
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Corporation Releases Letter to Shareholders
8. CEL-SCI Corporation Announces 2008 Financial Results
9. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a ... address unmet medical needs in women,s health, today ... present at the Cantor Fitzgerald Inaugural Healthcare Conference ... 4:45 PM EDTLocation: , Le Parker Meridien Hotel, ... www.juniperpharma.com, under  ,Investor, or  click here ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... filter that does not sacrifice selectivity to achieve faster flow rates in comparison ... fine pores with significant open space to allow easy liquid flow while trapping ...
(Date:6/30/2015)... ... ... Matrix Marketing Group, LLC , a leading provider of performance-based marketing ... its account management department as vice president of client services. Amanda Gregory joins ... and delivery expertise to the growing Matrix Marketing Group team in Denver, Colorado. ...
(Date:6/30/2015)... VANCOUVER , June 30, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... the first participant in its Phase 1/2 clinical ... of chronic unilateral Achilles tendinosis, has been enrolled ... to intra-tendon ultrasound-guided injections. RCT-01 is comprised of ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... International, Inc.,(Quest) announced they will show true 12-bit, ... and the Totoku, ME551i2,medical LCD display, at the ... be held in Seattle, Washington., Quest will ... Pro 8-Core workstation with two ME551i2 medical, LCD ...
... Call Scheduled Friday, April 4, 2008 at 8:30 a.m. EDT - ... Recent Highlights:, - 2007 pro forma consolidated net sales increased 21.2% year-over-year to ... $317.2 million, - Provided 2008 guidance: revenue ... of $28 million to $30 million, - ...
... 3, 2008 Spherix,Incorporated (Nasdaq: SPEX ) reported ... 31, 2007. The Company,s research and development costs,jumped to ... the launch of,the Company,s Phase 3 clinical trial for ... 2007. The trial is expected to last at least ...
Cached Biology Technology:Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images 2Chem Rx Corporation Reports Full Year 2007 Financial Results 2Chem Rx Corporation Reports Full Year 2007 Financial Results 3Chem Rx Corporation Reports Full Year 2007 Financial Results 4Chem Rx Corporation Reports Full Year 2007 Financial Results 5Chem Rx Corporation Reports Full Year 2007 Financial Results 6Chem Rx Corporation Reports Full Year 2007 Financial Results 7Chem Rx Corporation Reports Full Year 2007 Financial Results 8Chem Rx Corporation Reports Full Year 2007 Financial Results 9Chem Rx Corporation Reports Full Year 2007 Financial Results 10Chem Rx Corporation Reports Full Year 2007 Financial Results 11Chem Rx Corporation Reports Full Year 2007 Financial Results 12Chem Rx Corporation Reports Full Year 2007 Financial Results 13Chem Rx Corporation Reports Full Year 2007 Financial Results 14Chem Rx Corporation Reports Full Year 2007 Financial Results 15Spherix Reports 2007 Financial Results 2
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... change the world has seen in the last 100,000 years ... interglacial period. New research from the Niels Bohr Institute at ... the rise in temperature and the rise in the atmospheric ... time. The results have been published in the scientific journal, ...
... new study finds that mice have a distinct neural ... is associated with instinctually important smells such as those ... in Proceedings of the National Academy of Sciences ... have specially hardwired neural circuitry to trigger instinctive behavior ...
... breeders announced a new high-yielding variety of oats. ... height, withstands falling over (lodging), matures earlier and produces ... seed yield potential, exceeding the Rodgers variety by 20 ... 32.2-pound bushel compared to 31.9-pound bushel for Rodgers," said ...
Cached Biology News:Rise in temperatures and CO2 follow each other closely in climate change 2Rise in temperatures and CO2 follow each other closely in climate change 3Mice have distinct subsystem to handle smell associated with fear 2Mice have distinct subsystem to handle smell associated with fear 3Clemson plant breeders roll out new oat variety 2
Proliferin (N-14)...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... The Finnpipette BioControl is a major ... A complete liquid handling system - ... interchangeable tip cone modules. All five ... cone modules fit one handle. The ...
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
Biology Products: